➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Merck
Express Scripts
Colorcon
Harvard Business School

Last Updated: October 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,018,192

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,018,192 protect, and when does it expire?

Patent 9,018,192 protects ATRIPLA and is included in one NDA.

This patent has sixty-two patent family members in twenty-eight countries.

Summary for Patent: 9,018,192
Title:Unitary pharmaceutical dosage form
Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
Inventor(s): Dahl; Terrence C. (Sunnyvale, CA), Hussain; Munir A. (Belle Mead, NJ), Lipper; Robert A. (Pennington, NJ), Jerzewski; Robert L. (Belle Mead, NJ), Menning; Mark M. (San Francisco, CA), Oliyai; Reza (San Carlos, CA), Yang; Taiyin (Saratoga, CA)
Assignee: Bristol-Myers Squibb & Gilead Sciences, Inc. (Foster City, CA)
Application Number:14/050,714
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,018,192
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,018,192

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences ATRIPLA efavirenz; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 021937-001 Jul 12, 2006 AB RX Yes Yes   Start Trial   Start Trial TREATMENT OF HIV-1 INFECTION IN ADULTS   Start Trial
Gilead Sciences ATRIPLA efavirenz; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 021937-001 Jul 12, 2006 AB RX Yes Yes   Start Trial   Start Trial TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,018,192

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 054060   Start Trial
Argentina 054511   Start Trial
Austria 419839   Start Trial
Australia 2006257794   Start Trial
Australia 2006257795   Start Trial
Brazil PI0611634   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
AstraZeneca
McKinsey
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.